

20 February 2018

Resonance Health develops new assessment for the screening of NASH

Resonance Health (ASX: RHT) is pleased to announce today that it is releasing a new MRI-based assessment tool for the screening of non-alcoholic steatohepatitis (NASH) patients.

As part of the Company's aggressive R&D program of the past several years, and in recognition of the growing global clinical importance of non-alcoholic fatty liver disease (NAFLD), a tool has been developed to help clinicians identify those patients with NASH.

Considered a serious manifestation of NAFLD, it is estimated that approximately 25 million people in the United States alone have undiagnosed NASH, and of these, about 5 million are expected to develop cirrhosis and/or be diagnosed with hepatocellular carcinoma.

The Company anticipates that initial uptake of this technology will come from pharmaceutical companies engaged in the development of drugs to treat NASH. Resonance will be highlighting this new product for the first time at the upcoming NASH Engage Global conference in London on February 26-27 2018.

Martin Blake

Chairman RHT

For further information please contact:

Alison Laws

Chief Business Development Officer, Resonance Health

E: alisonl@resonancehealth.com P: +61 (0)8 9286 5300